Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) is now available.
Nanjing Leads Biolabs Co., Ltd. has announced its intention to implement an H Share Full Circulation program, which involves converting 44,391,598 unlisted shares into H shares, representing approximately 22.32% of its total issued share capital. This strategic move is aimed at enhancing the company’s market presence by facilitating the listing and circulation of these shares on the Hong Kong Stock Exchange, subject to regulatory approvals. The company has submitted the necessary filing materials to the China Securities Regulatory Commission and will proceed with further announcements as the process unfolds.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a joint stock company established in the People’s Republic of China, operating in the biotechnology sector. The company is involved in the development and provision of biotechnological products and services, with a focus on expanding its market presence through strategic initiatives such as the H Share Full Circulation program.
Average Trading Volume: 691,451
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$10.59B
For a thorough assessment of 9887 stock, go to TipRanks’ Stock Analysis page.